HIF2α Promotes Cancer Metastasis through TCF7L2-Dependent Fatty Acid Synthesis in ccRCC. 2024

Jian Shi, and Qingyang Lv, and Daojia Miao, and Zhiyong Xiong, and Zhihao Wei, and Songming Wu, and Diaoyi Tan, and Keshan Wang, and Xiaoping Zhang
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, P. R. China.

Recent studies have highlighted the notable involvement of the crosstalk between hypoxia-inducible factor 2 alpha (HIF2α) and Wnt signaling components in tumorigenesis. However, the cellular function and precise regulatory mechanisms of HIF2α and Wnt signaling interactions in clear cell renal cell carcinoma (ccRCC) remain elusive. To analyze the correlation between HIF2α and Wnt signaling, we utilized the Cancer Genome Atlas - Kidney Renal Clear Cell Carcinoma (TCGA-KIRC) public database, HIF2α RNA sequencing data, and conducted luciferase reporter assays. A Wnt-related gene set was employed to identify key regulators of Wnt signaling controlled by HIF2α in ccRCC. Furthermore, we assessed the biological effects of TCF7L2 on ccRCC metastasis and lipid metabolism in both in vivo and in vitro settings. Our outcomes confirm TCF7L2 as a key gene involved in HIF2α-mediated regulation of the canonical Wnt pathway. Functional studies demonstrate that TCF7L2 promotes metastasis in ccRCC. Mechanistic investigations reveal that HIF2α stabilizes TCF7L2 mRNA in a method based on m6A by transcriptionally regulating METTL3. Up-regulation of TCF7L2 enhances cellular fatty acid oxidation, which promotes histone acetylation. This facilitates the transcription of genes connected to epithelial-mesenchymal transition and ultimately enhances metastasis of ccRCC. These outcomes offer a novel understanding into the involvement of lipid metabolism in the signaling pathway regulation, offering valuable implications for targeted treatment in ccRCC.

UI MeSH Term Description Entries

Related Publications

Jian Shi, and Qingyang Lv, and Daojia Miao, and Zhiyong Xiong, and Zhihao Wei, and Songming Wu, and Diaoyi Tan, and Keshan Wang, and Xiaoping Zhang
June 2021, BMC cancer,
Jian Shi, and Qingyang Lv, and Daojia Miao, and Zhiyong Xiong, and Zhihao Wei, and Songming Wu, and Diaoyi Tan, and Keshan Wang, and Xiaoping Zhang
April 2022, Journal of cellular physiology,
Jian Shi, and Qingyang Lv, and Daojia Miao, and Zhiyong Xiong, and Zhihao Wei, and Songming Wu, and Diaoyi Tan, and Keshan Wang, and Xiaoping Zhang
February 2018, Cancer discovery,
Jian Shi, and Qingyang Lv, and Daojia Miao, and Zhiyong Xiong, and Zhihao Wei, and Songming Wu, and Diaoyi Tan, and Keshan Wang, and Xiaoping Zhang
January 2021, Oncology letters,
Jian Shi, and Qingyang Lv, and Daojia Miao, and Zhiyong Xiong, and Zhihao Wei, and Songming Wu, and Diaoyi Tan, and Keshan Wang, and Xiaoping Zhang
January 2024, Cell death discovery,
Jian Shi, and Qingyang Lv, and Daojia Miao, and Zhiyong Xiong, and Zhihao Wei, and Songming Wu, and Diaoyi Tan, and Keshan Wang, and Xiaoping Zhang
May 2022, Acta biochimica et biophysica Sinica,
Jian Shi, and Qingyang Lv, and Daojia Miao, and Zhiyong Xiong, and Zhihao Wei, and Songming Wu, and Diaoyi Tan, and Keshan Wang, and Xiaoping Zhang
October 2023, Cancer science,
Jian Shi, and Qingyang Lv, and Daojia Miao, and Zhiyong Xiong, and Zhihao Wei, and Songming Wu, and Diaoyi Tan, and Keshan Wang, and Xiaoping Zhang
February 2022, iScience,
Jian Shi, and Qingyang Lv, and Daojia Miao, and Zhiyong Xiong, and Zhihao Wei, and Songming Wu, and Diaoyi Tan, and Keshan Wang, and Xiaoping Zhang
January 2021, Frontiers in pharmacology,
Jian Shi, and Qingyang Lv, and Daojia Miao, and Zhiyong Xiong, and Zhihao Wei, and Songming Wu, and Diaoyi Tan, and Keshan Wang, and Xiaoping Zhang
April 2021, Nature cancer,
Copied contents to your clipboard!